APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy in CNS Disorder

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gene Therapy in CNS Disorder Market Outlook and Growth Opportunities 2026

Report ID 173994610421 December 2025192 pages

Choose your research edition.

Industry ResearchGene Therapy in CNS Disorder Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy in CNS Disorder Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Gene Therapy in CNS Disorder Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy in CNS Disorder Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy in CNS Disorder Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gene Therapy in CNS Disorder market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Therapy in CNS Disorder is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gene Therapy in CNS Disorder market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gene Therapy in CNS Disorder market include Novartis AG, Biogen, Voyager Therapeutics, Spark Therapeutics and Bluebird Bio Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gene Therapy in CNS Disorder market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Therapy in CNS Disorder and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Therapy in CNS Disorder revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy in CNS Disorder market.

Gene Therapy in CNS Disorder Segment by Company

Novartis AG

Biogen

Voyager Therapeutics

Spark Therapeutics

Bluebird Bio Inc.

Gene Therapy in CNS Disorder Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Gene Therapy in CNS Disorder Segment by Application

Parkinson's Disease

Huntington's Disease

Batten Disease

Alzheimer's Disease

Gene Therapy in CNS Disorder Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gene Therapy in CNS Disorder status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Therapy in CNS Disorder key companies, revenue, market share, and recent developments.

3. To split the Gene Therapy in CNS Disorder breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Therapy in CNS Disorder market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Therapy in CNS Disorder significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Therapy in CNS Disorder competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy in CNS Disorder market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy in CNS Disorder and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy in CNS Disorder.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy in CNS Disorder industry.

Chapter 3: Detailed analysis of Gene Therapy in CNS Disorder company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Therapy in CNS Disorder in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Therapy in CNS Disorder in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Therapy in CNS Disorder Industry Trends Table 2. Gene Therapy in CNS Disorder Industry Drivers Table 3. Gene Therapy in CNS Disorder Industry Opportunities and Challenges Table 4. Gene Therapy in CNS Disorder Industry Restraints Table 5. Global Gene Therapy in CNS Disorder Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Therapy in CNS Disorder Revenue Share by Company (2021-2026) Table 7. Global Gene Therapy in CNS Disorder Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Therapy in CNS Disorder Key Company Manufacturing Base & Headquarters Table 9. Global Gene Therapy in CNS Disorder Company, Product Type & Application Table 10. Global Gene Therapy in CNS Disorder Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Therapy in CNS Disorder by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Therapy Table 15. Significant Companies of Non-viral Gene Therapy Table 16. Global Gene Therapy in CNS Disorder Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene Therapy in CNS Disorder Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene Therapy in CNS Disorder Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene Therapy in CNS Disorder Sales Value Share by Type (2021-2026) Table 20. Global Gene Therapy in CNS Disorder Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Parkinson's Disease Table 22. Significant Companies of Huntington's Disease Table 23. Significant Companies of Batten Disease Table 24. Significant Companies of Alzheimer's Disease Table 25. Global Gene Therapy in CNS Disorder Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gene Therapy in CNS Disorder Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Gene Therapy in CNS Disorder Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Gene Therapy in CNS Disorder Sales Value Share by Application (2021-2026) Table 29. Global Gene Therapy in CNS Disorder Sales Value Share by Application (2027-2032) Table 30. Global Gene Therapy in CNS Disorder Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Gene Therapy in CNS Disorder Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Gene Therapy in CNS Disorder Sales Value Share by Region (2021-2026) Table 33. Global Gene Therapy in CNS Disorder Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Gene Therapy in CNS Disorder Sales Value Share by Region (2027-2032) Table 35. Global Gene Therapy in CNS Disorder Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Gene Therapy in CNS Disorder Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Gene Therapy in CNS Disorder Sales Value Market Share by Country (2021-2026) Table 38. Global Gene Therapy in CNS Disorder Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Gene Therapy in CNS Disorder Sales Value Market Share by Country (2027-2032) Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG Gene Therapy in CNS Disorder Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novartis AG Gene Therapy in CNS Disorder Product Portfolio Table 44. Novartis AG Recent Development Table 45. Biogen Company Information Table 46. Biogen Business Overview Table 47. Biogen Gene Therapy in CNS Disorder Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Biogen Gene Therapy in CNS Disorder Product Portfolio Table 49. Biogen Recent Development Table 50. Voyager Therapeutics Company Information Table 51. Voyager Therapeutics Business Overview Table 52. Voyager Therapeutics Gene Therapy in CNS Disorder Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio Table 54. Voyager Therapeutics Recent Development Table 55. Spark Therapeutics Company Information Table 56. Spark Therapeutics Business Overview Table 57. Spark Therapeutics Gene Therapy in CNS Disorder Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio Table 59. Spark Therapeutics Recent Development Table 60. Bluebird Bio Inc. Company Information Table 61. Bluebird Bio Inc. Business Overview Table 62. Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio Table 64. Bluebird Bio Inc. Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Gene Therapy in CNS Disorder Product Image Figure 2. Global Gene Therapy in CNS Disorder Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy in CNS Disorder Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Therapy in CNS Disorder Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Therapy Image Figure 8. Non-viral Gene Therapy Image Figure 9. Global Gene Therapy in CNS Disorder Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene Therapy in CNS Disorder Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene Therapy in CNS Disorder Sales Value Share by Type (2021-2032) Figure 12. Parkinson's Disease Image Figure 13. Huntington's Disease Image Figure 14. Batten Disease Image Figure 15. Alzheimer's Disease Image Figure 16. Global Gene Therapy in CNS Disorder Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Gene Therapy in CNS Disorder Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Gene Therapy in CNS Disorder Sales Value Share by Application (2021-2032) Figure 19. Global Gene Therapy in CNS Disorder Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Gene Therapy in CNS Disorder Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Gene Therapy in CNS Disorder Sales Value (2021-2032) & (US$ Million) Figure 22. North America Gene Therapy in CNS Disorder Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Gene Therapy in CNS Disorder Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Gene Therapy in CNS Disorder Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Gene Therapy in CNS Disorder Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Gene Therapy in CNS Disorder Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Gene Therapy in CNS Disorder Sales Value (2021-2032) & (US$ Million) Figure 28. South America Gene Therapy in CNS Disorder Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Gene Therapy in CNS Disorder Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Gene Therapy in CNS Disorder Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Parkinson's Disease
  • Huntington's Disease
  • Batten Disease
  • Alzheimer's Disease
Companies covered
  • Novartis AG
  • Biogen
  • Voyager Therapeutics
  • Spark Therapeutics
  • Bluebird Bio Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Therapy in CNS Disorder Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Therapy in CNS Disorder Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Therapy in CNS Disorder Market Dynamics
  1. 2.1 Gene Therapy in CNS Disorder Industry Trends
  2. 2.2 Gene Therapy in CNS Disorder Industry Drivers
  3. 2.3 Gene Therapy in CNS Disorder Industry Opportunities and Challenges
  4. 2.4 Gene Therapy in CNS Disorder Industry Restraints
3 Gene Therapy in CNS Disorder Market by Company
  1. 3.1 Global Gene Therapy in CNS Disorder Company Revenue Ranking in 2025
  2. 3.2 Global Gene Therapy in CNS Disorder Revenue by Company (2021-2026)
  3. 3.3 Global Gene Therapy in CNS Disorder Company Ranking (2024-2026)
  4. 3.4 Global Gene Therapy in CNS Disorder Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Therapy in CNS Disorder Company Product Type and Application
  6. 3.6 Global Gene Therapy in CNS Disorder Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Therapy in CNS Disorder Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Therapy in CNS Disorder Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy in CNS Disorder Market by Type
  1. 4.1 Gene Therapy in CNS Disorder Type Introduction
  2. 4.1.1 Viral Gene Therapy
  3. 4.1.2 Non-viral Gene Therapy
  4. 4.2 Global Gene Therapy in CNS Disorder Sales Value by Type
  5. 4.2.1 Global Gene Therapy in CNS Disorder Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene Therapy in CNS Disorder Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene Therapy in CNS Disorder Sales Value Share by Type (2021-2032)
5 Gene Therapy in CNS Disorder Market by Application
  1. 5.1 Gene Therapy in CNS Disorder Application Introduction
  2. 5.1.1 Parkinson's Disease
  3. 5.1.2 Huntington's Disease
  4. 5.1.3 Batten Disease
  5. 5.1.4 Alzheimer's Disease
  6. 5.2 Global Gene Therapy in CNS Disorder Sales Value by Application
  7. 5.2.1 Global Gene Therapy in CNS Disorder Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gene Therapy in CNS Disorder Sales Value by Application (2021-2032)
  9. 5.2.3 Global Gene Therapy in CNS Disorder Sales Value Share by Application (2021-2032)
6 Gene Therapy in CNS Disorder Regional Value Analysis
  1. 6.1 Global Gene Therapy in CNS Disorder Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Therapy in CNS Disorder Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Therapy in CNS Disorder Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Therapy in CNS Disorder Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Therapy in CNS Disorder Sales Value (2021-2032)
  7. 6.3.2 North America Gene Therapy in CNS Disorder Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Therapy in CNS Disorder Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Therapy in CNS Disorder Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Therapy in CNS Disorder Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Therapy in CNS Disorder Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Therapy in CNS Disorder Sales Value (2021-2032)
  16. 6.6.2 South America Gene Therapy in CNS Disorder Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Therapy in CNS Disorder Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Therapy in CNS Disorder Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy in CNS Disorder Country-level Value Analysis
  1. 7.1 Global Gene Therapy in CNS Disorder Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Therapy in CNS Disorder Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Therapy in CNS Disorder Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Therapy in CNS Disorder Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Therapy in CNS Disorder Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Therapy in CNS Disorder Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Therapy in CNS Disorder Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Gene Therapy in CNS Disorder Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Biogen
  8. 8.2.1 Biogen Company Information
  9. 8.2.2 Biogen Business Overview
  10. 8.2.3 Biogen Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biogen Gene Therapy in CNS Disorder Product Portfolio
  12. 8.2.5 Biogen Recent Developments
  13. 8.3 Voyager Therapeutics
  14. 8.3.1 Voyager Therapeutics Company Information
  15. 8.3.2 Voyager Therapeutics Business Overview
  16. 8.3.3 Voyager Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio
  18. 8.3.5 Voyager Therapeutics Recent Developments
  19. 8.4 Spark Therapeutics
  20. 8.4.1 Spark Therapeutics Company Information
  21. 8.4.2 Spark Therapeutics Business Overview
  22. 8.4.3 Spark Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio
  24. 8.4.5 Spark Therapeutics Recent Developments
  25. 8.5 Bluebird Bio Inc.
  26. 8.5.1 Bluebird Bio Inc. Company Information
  27. 8.5.2 Bluebird Bio Inc. Business Overview
  28. 8.5.3 Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio
  30. 8.5.5 Bluebird Bio Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst